GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT04779697
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • GLP-1 analogue - semaglutide — DRUG
    GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
  • Placebo — OTHER
    Placebo - administered once weekly for a total of 12 weeks

Study Details

To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.

Key Dates

Start date
Feb 1, 2021
Status verified
Jan 2026
Primary completion
Nov 19, 2024
Completion
Nov 19, 2024

Study Design

Enrollment
96 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: GLP-1a
    GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks
  • Placebo Comparator: Placebo
    Placebo pen administered weekly over 12 weeks

Primary Outcome Measure

Change in Craving Score [ Time Frame: Average change in avg FCI craving score from week 0 to end of treatment (week 12) computed as avg FCI score at week 12 - avg FCI score at Week 0. ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Yale Stress Center: Yale UniversityNew HavenConnecticut06519-

Related coverage on Hipa.ai

Find similar trials in New Haven, CT

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
The Yale Stress Center: Yale University· New Haven, CT

Related Studies